Evaluation and management of overactive bladder: strategies for optimizing care

Figures & data

Table 1 American Urological Association recommendations for overactive bladder therapy

Level of therapy	Type of therapy	Examples of therapy
First-line therapy	Behavioral therapy	Bladder diet, bladder training, pelvic floor physical therapy, and biofeedback
Second-line therapy	Medical therapy	Anticholinergic medication and β3 agonist medication
Third-line therapya	Neuromodulation	PTNS®, InterStim®, and Botox®

Notes:

a Data from reference 28. To meet criteria, patients must have failed first-line therapy and second-line therapy (or cannot tolerate medications due to contraindications or side effects).

Abbreviation: PTNS, percutaneous tibial nerve stimulation.

Table 2 Overactive bladder medications

Medication brand (generic)	Dosage	Route	t1/2 (hours)
Detrola (tolterodine tartrate)	2 mg or 4 mg bid vs daily	Oral	8
Ditropana (oxybutynin chloride)	5 mg, 10 mg, or 15 mg bid, tid, or daily	Oral	12–13b
Oxytrol (oxybutynin)	3.9 mg/d patch twice weekly	Transdermal patch	7–8b
Gelnique (oxybutynin)	3% three pumps (84 mg) daily and 10% one sachet (100 mg) daily	Transdermal gel	NA
Toviaz (fesoterodine)	4 mg or 8 mg daily	Oral	7–8b
Enablex (darifenacin hydrobromide)	7.5 mg or 15 mg daily	Oral	12
Vesicare (solifenacin succinate)	5 mg or 10 mg daily	Oral	45–68b
Sanctura (trospium chloride)	20 mg bid	Oral	18.3
Sanctura XR (trospium chloride)	60 mg daily	Oral	36
Myrbetriq (mirabegron)	25 mg or 50 mg daily	Oral	50

Notes:

a Available in short-acting and long-acting formulations.

b This data is presented as range.

Abbreviations: bid, twice daily; d, day; NA, not available; t_1/2, half life; tid, three times daily; XR, extended release.